Psychopharmacology of Eating Disorders in Children and Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 121-138

  Golden, Neville H ^a   Attia, Evelyn ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Adolescents; Children; Eating Disorders; Pharmacology; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; ONDANSETRON; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; ZONISAMIDE;

ANOREXIA NERVOSA; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BINGE EATING DISORDER; BULIMIA; COGNITIVE THERAPY; COMORBIDITY; DECREASED APPETITE; DEPRESSION; DIABETES MELLITUS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EATING DISORDER; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; GRAND MAL SEIZURE; GROWTH RETARDATION; HEALTH CARE NEED; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; INSOMNIA; INSULIN RESISTANCE; INTERMETHOD COMPARISON; MEMORY DISORDER; MENTAL CONCENTRATION; METABOLIC ACIDOSIS; METABOLIC SYNDROME X; NAUSEA; NEPHROLITHIASIS; NIGHT EATING SYNDROME; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEX RATIO; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TACHYCARDIA; TARDIVE DYSKINESIA; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; CHILD; COMORBIDITY; EATING DISORDERS; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 79251545208     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.11.001     Document Type: Review

References (85)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision ed, American Psychiatric Association, Washington, DC. 4th edition.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders version 5: proposed criteria. dsm5.org Available at:, Accessed January 1, 2010. http://www.dsm5.org/proposedrevisions/pages/eatingdisorders.aspx.
3. Hoek H., van Hoeken D. Review of the prevalence and incidence of eating disorders. Int J Eat Disord 2003, 34(4):383-396.
4. Hudson J.I., Hiripi E., Pope H.G., et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007, 61(3):348-358.
5. Keski-Rahkonen A., Sihvola E., Raevuori A., et al. Reliability of self-reported eating disorders: optimizing population screening. Int J Eat Disord 2006, 39(8):754-762.
6. Machado P.P., Machado B.C., Goncalves S., et al. The prevalence of eating disorders not otherwise specified. Int J Eat Disord 2007, 40(3):212-217.
7. Rodriguez-Cano T., Beato-Fernandez L. Attitudes towards change and treatment outcome in eating disorders. Eat Weight Disord 2005, 10(1):59-65.
8. Tanofsky-Kraff M., Yanovski S., Wilfley D., et al. Eating-disordered behaviors, body fat, and psychopathology in overweight and normal-weight children. J Consult Clin Psychol 2004, 72(1):53-61.
9. Tanofsky-Kraff M., Faden D., Yanovski S., et al. The perceived onset of dieting and loss of control eating behaviors in overweight children. Int J Eat Disord 2005, 38(2):112-122.
10. Goossens L., Braet C., Decaluwé V. Loss of control over eating in obese youngsters. Behav Res Ther 2007, 45(1):1-9.
11. Glasofer D., Tanofsky-Kraff M., Eddy K., et al. Binge eating in overweight treatment-seeking adolescents. J Pediatr Psychol 2007, 32(1):95-105.
12. Levine M., Ringham R., Kalarchian M., et al. Overeating among seriously overweight children seeking treatment: results of the children's eating disorder examination. Int J Eat Disord 2006, 39(2):135-140.
13. Goldschmidt A., Aspen V., Sinton M., et al. Disordered eating attitudes and behaviors in overweight youth. Obesity (Silver Spring) 2008, 16(2):257-264.
14. Nattiv A., Loucks A., Manore M., et al. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 2007, 39(10):1867-1882.
15. Nicholls D., Chater R., Lask B. Children into DSM don't go: a comparison of classification systems for eating disorders in childhood and early adolescence. Int J Eat Disord 2000, 28(3):317-324.
16. Walsh B.T.B.C., Fairburn C.G., Halmi K.A., et al. Defining eating disorders. Treating and preventing adolescent mental health disorders: what we know and what we don't know 2005, 258-281. Oxford University Press, The Annenberg Foundation Trust at Sunnylands, and the Annenberg Public Policy Center of the University of Pennsylvania, New York. D.L. Evans, E.B. Foa, R.E. Gur (Eds.).
17. Halmi K. The perplexities of conducting randomized, double-blind, placebo-controlled treatment trials in anorexia nervosa patients. Am J Psychiatry 2008, 165(10):1227-1228.
18. Lacey J., Crisp A. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J 1980, 56(Suppl 1):79-85.
19. Halmi K., Eckert E., LaDu T., et al. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986, 43(2):177-181.
20. Biederman J., Herzog D., Rivinus T., et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol 1985, 5(1):10-16.
21. Geller D., Biederman J., Stewart S., et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003, 160(11):1919-1928.
22. Kaye W., Gwirtsman H., George D., et al. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalize after weight gain. Biol Psychiatry 1988, 23(1):102-105.
23. Kaye W., Gwirtsman H., George D., et al. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?. Arch Gen Psychiatry 1991, 48(6):556-562.
24. Attia E., Haiman C., Walsh B., et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa?. Am J Psychiatry 1998, 155(4):548-551.
25. Holtkamp K., Konrad K., Kaiser N., et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 2005, 39(3):303-310.
26. Kaye W., Nagata T., Weltzin T., et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001, 49(7):644-652.
27. Walsh B., Kaplan A., Attia E., et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006, 295(22):2605-2612.
28. Boachie A., Goldfield G., Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord 2003, 33(1):98-103.
29. Mehler C., Wewetzer C., Schulze U., et al. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry 2001, 10(2):151-157.
30. Mehler-Wex C., Romanos M., Kirchheiner J., et al. Atypical antipsychotics in severe anorexia nervosa in children and adolescents-review and case reports. Eur Eat Disord Rev 2008, 16(2):100-108.
31. Powers P., Santana C., Bannon Y. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002, 32(2):146-154.
32. Barbarich N., McConaha C., Gaskill J., et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004, 65(11):1480-1482.
33. Leggero C., Masi G., Brunori E., et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol 2010, 20(2):127-133.
34. Brambilla F., Garcia C., Fassino S., et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007, 22(4):197-204.
35. Bissada H., Tasca G., Barber A., et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008, 165(10):1281-1288.
36. Powers P., Bannon Y., Eubanks R., et al. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord 2007, 40(1):21-26.
37. Bosanac P., Kurlender S., Norman T., et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007, 22(4):223-230.
38. Fisman S., Steele M., Short J., et al. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry 1996, 35(7):937-940.
39. Newman-Toker J. Risperidone in anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2000, 39(8):941-942.
40. Kaye W., Gendall K., Strober M. Nutrition, serotonin and behavior in anorexia and bulimia nervosa. Nestle Nutr Workshop Ser Clin Perform Programme 2001, 5:153-165. [discussion: 165-158].
41. Barbarich N.C., McConaha C.W., Halmi K.A., et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord 2004, 35(1):10-15.
42. McKnight R., Park R. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 2010, 18(1):10-21.
43. Walsh B.T., Stewart J.W., Roose S.P., et al. A double-blind trial of phenelzine in bulimia. J Psychiatr Res 1985, 19(2-3):485-489.
44. Shapiro J.R., Berkman N.D., Brownley K.A., et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007, 40(4):321-336.
45. Goldstein D.J., Wilson M.G., Ascroft R.C., et al. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord 1999, 25(1):19-27.
46. Alger S.A., Schwalberg M.D., Bigaouette J.M., et al. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991, 53(4):865-871.
47. Walsh B.T., Stewart J.W., Roose S.P., et al. Treatment of bulimia with phenelzine. A double-blind, placebo-controlled study. Arch Gen Psychiatry 1984, 41(11):1105-1109.
48. Rothschild R., Quitkin H.M., Quitkin F.M., et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int J Eat Disord 1994, 15(1):1-9.
49. Horne R.L., Ferguson J.M., Pope H.G., et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988, 49(7):262-266.
50. Beumont P.J., Russell J.D., Touyz S.W., et al. Intensive nutritional counselling in bulimia nervosa: a role for supplementation with fluoxetine?. Aust N Z J Psychiatry 1997, 31(4):514-524.
51. Fichter M.M., Leibl K., Rief W., et al. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 1991, 24(1):1-7.
52. Fluoxetine Bulimia Nervosa Collaborative Study Group Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992, 42(2):139-147.
53. Goldstein D.J., Wilson M.G., Thompson V.L., et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 1995, 166(5):660-666.
54. Kanerva R., Rissanen A., Sarna S. Fluoxetine in the treatment of anxiety, depressive symptoms, and eating-related symptoms in bulimia nervosa. Nord J Psychiatry 1995, 49:237-242.
55. Romano S.J., Halmi K.A., Sarkar N.P., et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002, 159(1):96-102.
56. Walsh B.T., Sysko R., Parides M.K. Early response to desipramine among women with bulimia nervosa. Int J Eat Disord 2006, 39(1):72-75.
57. Sysko R., Sha N., Wang Y., et al. Early response to antidepressant treatment in bulimia nervosa. Psychol Med 2010, 40(6):999-1005.
58. Kotler L.A., Devlin M.J., Davies M., et al. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol 2003, 13(3):329-335.
59. Eliasson B., Gudbjornsdottir S., Cederholm J., et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 2007, 31(7):1140-1147.
60. McElroy S.L., Hudson J.I., Capece J.A., et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007, 61(9):1039-1048.
61. Hedges D.W., Reimherr F.W., Hoopes S.P., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003, 64(12):1449-1454.
62. Hoopes S.P., Reimherr F.W., Hedges D.W., et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003, 64(11):1335-1341.
63. Nickel C., Tritt K., Muehlbacher M., et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005, 38(4):295-300.
64. Schatzberg A., Cole J., DeBatistia C. Manual of clinical psychomarmacology 2003, American Psychiatric Association, Washington, DC. 4th edition.
65. Faris P.L., Kim S.W., Meller W.H., et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000, 355(9206):792-797.
66. Arnold L.M., McElroy S.L., Hudson J.I., et al. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002, 63(11):1028-1033.
67. Grilo C.M., Masheb R.M., Wilson G.T. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry 2005, 57(3):301-309.
68. Hudson J.I., McElroy S.L., Raymond N.C., et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998, 155(12):1756-1762.
69. Pearlstein T., Spurell E., Hohlstein L.A., et al. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health 2003, 6(2):147-151.
70. McElroy S.L., Casuto L.S., Nelson E.B., et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000, 157(6):1004-1006.
71. McElroy S.L., Hudson J.I., Malhotra S., et al. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry 2003, 64(7):807-813.
72. Guerdjikova A.I., McElroy S.L., Kotwal R., et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol 2008, 23(1):1-11.
73. Reas D.L., Grilo C.M. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 2008, 16(9):2024-2038.
74. Grilo C.M., Masheb R.M., Salant S.L. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2005, 57(10):1193-1201.
75. Ricca V., Mannucci E., Mezzani B., et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001, 70(6):298-306.
76. Appolinario J.C., Bacaltchuk J., Sichieri R., et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003, 60(11):1109-1116.
77. Milano W., Petrella C., Casella A., et al. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005, 22(1):25-31.
78. Wilfley D.E., Crow S.J., Hudson J.I., et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008, 165(1):51-58.
79. Golay A., Laurent-Jaccard A., Habicht F., et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005, 13(10):1701-1708.
80. McElroy S.L., Guerdjikova A., Kotwal R., et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007, 68(3):390-398.
81. O'Reardon J.P., Allison K.C., Martino N.S., et al. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry 2006, 163(5):893-898.
82. Lock J., Agras W., Bryson S., et al. A comparison of short- and long-term family therapy for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2005, 44(7):632-639.
83. Couturier J., Lock J. A review of medication use for children and adolescents with eating disorders. J Can Acad Child Adolesc Psychiatry 2007, 16(4):173-176.
84. American Psychiatric Association Treatment of patients with eating disorders, third edition. American Psychiatric Association. Am J Psychiatry 2006, 163:4-54.
85. National Institute for Clinical Excellence 2004 Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders London: National Institute of Clinical Excellence. Available at:, Accessed 9/1/2010. http://guidance.nice.org.uk/CG9/NICEGuidance/pdf/English.